CHICAGO — Patients with diabetes who used GLP-1 receptor agonists demonstrated lower risks for certain rheumatic diseases, including rheumatoid arthritis and gout, according to data presented at ACR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback